icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Pharmacokinetics of ABT-493 and ABT-530 is Similar in
Healthy Caucasian, Han Chinese, and Japanese Adult Subjects

 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Tianli Wang1, Wei Liu2, Armen Asatryan3, Jingtao Wu2, Andrew Campbell3, Jens Kort3, Sandeep Dutta2 1Former AbbVie employee, Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA 2Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA 3HCV Clinical Development, AbbVie, North Chicago, IL, USA
 
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage......
http://www.natap.org/2014/CROI/croi_14.htm
 
A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance......
http://www.natap.org/2014/AASLD/AASLD_51.htm
 
ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance.....
http://www.natap.org/2014/CROI/croi_11.htm
 

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif